Published on November 11, 2009 at 4:23 AM
Reportlinker.com announces that a new market research report is available in its catalogue.
Neurodegenerative Disorder Therapies
With a market size of US$14.5 billion in 2005 and an anticipated value of US$16.5 billion in 2006, the neurodegenerative market represents a valuable, fast-growing opportunity in the pharma/biotech industry. An increase in the number of aged people, increased life expectancy, unmet clinical needs together with advances in treatments of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease will continue to contribute to the expansion of the global market.
This report provides an insight into the neurodegenerative market, neurotherapeutic drugs currently available, and upcoming products. This report specifically focuses on key CNS diseases, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, and neuropathies. Profiles of leading companies that are active in R&D in these areas are included.
The report presents, in detail, an overview of the current global market for neurodegenerative drugs for selected neurological diseases, including currently marketed and forthcoming neurotherapeutic products. Market analysis and assessment for key neurodegenerative therapies is done across major pharmaceutical markets in United States (US)/North America, Europe and Japan.
Key features of this report:
- Statistical information for selected neurological diseases
- Overview of the disease, key therapies, market size and growth, market composition by region, as well as market outlook and forecast
- Global sales figures for key neurodegenerative therapies
- Financial forecasts by disease and key product
- Description of neurotherapeutic products currently on the market, including a description of products in the pipeline
- Company profiles of major pharmaceutical providers active in R&D in these areas
- The report also deals with factors affecting growth, new drug therapies, and clinical research in the completion stages.
SOURCE Reportlinker